• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Adagene Inc.

    3/24/25 8:00:18 AM ET
    $ADAG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email
    6-K 1 tm2423673d2_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-
    16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of March 2025

     

    Commission File Number: 001-39997

     

     

     

    Adagene Inc.

     

     

     

    4F, Building C14, No. 218

    Xinghu Street, Suzhou Industrial Park

    Suzhou, Jiangsu Province, 215123

    People’s Republic of China

    +86-512-8777-3632

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Adagene Inc.
       
      By: /s/ Peter Luo
      Name: Peter Luo
      Title: Chief Executive Officer
       
    Date: March 24, 2025  

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit   Description
         
    99.1   Press Release titled “Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update”

     

     

     

    Get the next $ADAG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAG

    DatePrice TargetRatingAnalyst
    1/31/2025Overweight → Equal-Weight
    Morgan Stanley
    2/1/2022$27.00 → $15.00Overweight
    Morgan Stanley
    More analyst ratings

    $ADAG
    SEC Filings

    See more
    • SEC Form EFFECT filed by Adagene Inc.

      EFFECT - Adagene Inc. (0001818838) (Filer)

      6/2/25 12:15:19 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Adagene Inc.

      424B5 - Adagene Inc. (0001818838) (Filer)

      5/30/25 5:05:49 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form F-3/A filed by Adagene Inc.

      F-3/A - Adagene Inc. (0001818838) (Filer)

      5/23/25 4:06:11 PM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adagene downgraded by Morgan Stanley

      Morgan Stanley downgraded Adagene from Overweight to Equal-Weight

      1/31/25 8:29:36 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Adagene with a new price target

      Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously

      2/1/22 9:41:00 AM ET
      $ADAG
      Biotechnology: Pharmaceutical Preparations
      Health Care